151 related articles for article (PubMed ID: 36251574)
1. Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data.
Joyce DD; Wymer KM; Sharma V; Moriarty JP; Borah BJ; Geynisman DM; Plimack ER; Costello BA; Pagliaro LC; Boorjian SA
Cancer; 2022 Dec; 128(24):4194-4202. PubMed ID: 36251574
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
3. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C; Gravis G; Flechon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulie M; Allory Y; Harter V; Culine S;
Lancet Oncol; 2024 Feb; 25(2):255-264. PubMed ID: 38142702
[TBL] [Abstract][Full Text] [Related]
4. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Pfister C; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulié M; Allory Y; Harter V; Culine S;
J Clin Oncol; 2022 Jun; 40(18):2013-2022. PubMed ID: 35254888
[TBL] [Abstract][Full Text] [Related]
5. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
[TBL] [Abstract][Full Text] [Related]
6. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities.
Ruplin AT; Spengler AMZ; Montgomery RB; Wright JL
Clin Genitourin Cancer; 2020 Oct; 18(5):e557-e562. PubMed ID: 32201105
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
8. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
Montazeri K; Dranitsaris G; Thomas JD; Curran C; Preston MA; Steele GS; Kilbridge KL; Mantia C; Ravi P; McGregor BA; Mossanen M; Sonpavde G
Urol Oncol; 2021 Dec; 39(12):834.e1-834.e7. PubMed ID: 34162500
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine S; Harter V; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Abadie-Lacourtoisie S; Geoffrois L; Fiore FD; Roubaud G; Barthélémy P; Voog E; Emambux S; Serrate C; Saldana C; Nguyen-Tan-Hon T; Loriot Y; Eymard JC; Huillard O; Rolland F; Houédé N; Spano JP; Demery ME; Vieillot S; L'Haridon T; Hilgers W; Allory Y; Pfister C;
Clin Genitourin Cancer; 2021 Dec; 19(6):554-562. PubMed ID: 34602349
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
12. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer.
Kaneko G; Kikuchi E; Matsumoto K; Obata J; Nakamura S; Miyajima A; Oya M
Jpn J Clin Oncol; 2011 Jul; 41(7):908-14. PubMed ID: 21665907
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy.
Hemenway G; Lewis B; Ghatalia P; Anari F; Plimack ER; Kokate R; Handorf E; Deng M; Geynisman DM; Zibelman M
Eur Urol Oncol; 2023 Aug; 6(4):431-436. PubMed ID: 35792045
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer.
Stevenson SM; Danzig MR; Ghandour RA; Deibert CM; Decastro GJ; Benson MC; McKiernan JM
Urol Oncol; 2014 Nov; 32(8):1172-7. PubMed ID: 24998787
[TBL] [Abstract][Full Text] [Related]
18. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
[TBL] [Abstract][Full Text] [Related]
19. Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes.
Aydh A; Sari Motlagh R; Alamri A; Yanagisawa T; Ayed A; Rajwa P; Laukhtina E; Alasiri SM; Kawada T; Mostafai H; Ayidh A; Pallauf M; König F; Abufaraj M; Karakiewicz PI; Shariat SF
World J Urol; 2023 Aug; 41(8):2185-2194. PubMed ID: 37347252
[TBL] [Abstract][Full Text] [Related]
20. Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study.
Kitamura H; Hinotsu S; Tsukamoto T; Shibata T; Mizusawa J; Kobayashi T; Miyake M; Nishiyama N; Kojima T; Nishiyama H;
Jpn J Clin Oncol; 2020 Dec; 50(12):1464-1469. PubMed ID: 32699909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]